Screener
Corcept Therapeutics CORT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's EBITDA margin?
- Corcept Therapeutics (CORT) reported EBITDA margin of 1% in Q2 2026.
- How has Corcept Therapeutics's EBITDA margin changed year-over-year?
- Corcept Therapeutics's EBITDA margin decreased by 92.9% year-over-year, from 14.4% to 1%.
- What is the long-term trend for Corcept Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Corcept Therapeutics's EBITDA margin has grown at a -30.2% compound annual growth rate (CAGR), from 36.4% to 6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Corcept Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude